Kyle Eastman

Kyle Eastman is Vice President and Head of Chemistry at Halda Therapeutics in New Haven, CT, where he and his colleagues have invented the novel bifunctional technology, RIPTAC Therapeutics. The Halda team progressed their lead prostate program into the clinic in Feb 2025. Previously, Kyle was a program leader at Achillion where he helped advance the complement pipeline including support for the notable Factor D program and initiation of an additional complement pathway discovery program that together contributed to a near $1 billion acquisition by Alexion. Before Achillion, Kyle had spent almost a decade working across several virology programs at BMS in Wallingford, CT. During this time Kyle and his lab invented and contributed to several compounds advanced to the internal BMS development organization including the invention of the first pan-genotype HCV inhibitor which was predicted to be an orally bioavailable once daily treatment in humans. Additional efforts from his lab resulted in the invention of a host of orally bioavailable lead compounds targeting a novel HIV target that became a focal point in the BMS HIV divestiture to ViiV/GSK. Prior to beginning his career at BMS, Kyle spent two years at The Scripps Research Institute (TSRI) in La Jolla, CA under the mentorship of Phil Baran for post-doctoral studies. Kyle earned his PhD in synthetic organic chemistry at The Pennsylvania State University in 2006.